Aldeyra Therapeutics

United States
Prairie City, Iowa, United States, 01803

Company profile

Aldeyra Therapeutics company profile

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Business identity

Contact email
[email protected]
Phone number
+1 781 761 4904
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2004-01-01, Year

Headquarters

Postal code
01803
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
5
Total equity funding
$227.4M
Last funding
Post IPO Equity / $125M / 2021-04-28
Last equity funding
Post IPO Equity / $125M
Investors
1
Lead investors
1
Founders
2
Articles
266
Exited on
2014-05-05

Founders and investors

Founders

John E. DowlingThomas A. Jordan

Lead investors

Hercules Capital

Investors

Hercules Capital